Pfizer Thinks First-In-Class KHK Mechanism Could Work For NASH, Diabetes

Pfizer has high hopes for ketohexokinase inhibition and other fat-reducing mechanisms in NASH. Data from a small study reported at EASL also suggest its KHK inhibitor could have utility in diabetes.

Hepatitis

Pfizer Inc. boasts deep pockets and R&D expertise in a broad range of therapeutic areas, but it generally isn’t regarded yet as one of the big players in non-alcoholic steatohepatitis (NASH). However, the big pharma has four NASH candidates in clinical development – each of which takes a hepatic fat-reduction approach to the multifactorial disease – and has begun talking up its first-in-class, Phase II ketohexokinase (KHK) inhibitor for the disease.

Pfizer presented data from a 53-patient Phase II study of PF-06835919 at the European Association for the Study of the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category